Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675844 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
A Phase 2 study of HIV Infections, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT00675844 is a Phase 2 study of HIV Infections that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 7 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00675844, a Phase 2 study of HIV Infections, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
Conditions Studied
Interventions
- DRUG Elvucitabine
Study Locations (5)
Florida
- Clinical Trial Site - Orlando
- Clinical Trial Site - Pensacola
Texas
- Clinical Trial Site - Austin
- Clinical Trial Site - Dallas
New Jersey
- Clinical Trial Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675844
The ClinicalTrials.gov registry entry for NCT00675844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Elvucitabine is the first listed.
NCT00675844 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00675844 about?
NCT00675844 is a clinical study titled "An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment". Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
What is the current status of trial NCT00675844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2010-03.
What conditions does trial NCT00675844 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00675844?
The interventions under investigation include: Elvucitabine (DRUG).
Who is sponsoring clinical trial NCT00675844?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00675844 being conducted?
This trial has 5 study locations across Florida, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.